source
- Moderna raises $2 billion after Phase 3 success of its algorithm-driven personalized cancer vaccine with MerckModerna announced a $2 billion convertible debt financing, a move that follows the Phase 3 success of its personalized cancer vaccine developed with Merck. The vaccine relies on software that scan…
- FDA approves Roivant's brepocitinib for rare autoimmune disease dermatomyositisOn Thursday the U.S. Food and Drug Administration gave its nod to a new therapy from Roivant Sciences and its subsidiary Priovant. The oral medication, brepocitinib, will be sold under the brand na…